Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 18/20 | 0.87 |
| ▸ | EGFR | P00533 | 18/20 | 0.87 |
| ▸ | SRC | P12931 | 2/20 | 0.87 |
| ▸ | KDR | P35968 | 2/20 | 0.87 |
| ▸ | STK4 | Q13043 | 2/20 | 0.87 |
| ▸ | STK25 | O00506 | 1/20 | 0.87 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.87 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.87 |
| ▸ | GAK | O14976 | 1/20 | 0.87 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.87 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.87 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.87 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.87 |
| ▸ | STK17B | O94768 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.87 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129397 | 0.96 | EGFR (0.84) | ERBB2EGFRSRCKDRSTK4 | |
| SCHEMBL24037452 | 0.95 | ERBB2 (0.89) | ERBB2EGFRSRCKDRSTK4 | |
| SCHEMBL2130964 | 0.93 | ERBB2 (0.86) | ERBB2EGFRSRCKDRSTK4 | |
| Neratinib SCHEMBL15163655 | 0.93 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK4 | |
| Neratinib SCHEMBL571762 | 0.93 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK4 | |
| Neratinib SCHEMBL29394766 | 0.93 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK4 | |
| Neratinib SCHEMBL571763 | 0.93 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK4 | |
| Neratinib SCHEMBL15163654 | 0.93 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK4 | |
| Neratinib SCHEMBL29801657 | 0.93 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK4 | |
| Neratinib SCHEMBL29376313 | 0.93 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230175069-A1 | COMPOSITIONS AND METHODS FOR DETECTING GENE FUSIONS OF ESR1 AND CCDC170 FOR DETERMINING INCREASED RESISTANCE TO ENDOCRINE THERAPY AND FOR CANCER TREATMENT | UNITED STATES GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| EP-3488866-A1 | ANTINEOPLASTIC COMBINATIONS WITH MTOR INHIBITOR, HERCEPTIN, AND/OR HKI-272 | Wyeth LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | EGFR, ERBB2, ERBB3 | ERBB2 2/4885EGFR 1/4885SRC 20/4885 |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | ERBB2 7/4885EGFR 48/4885SRC 176/4885 |
| US-20230175069-A1 | COMPOSITIONS AND METHODS FOR DETECTING GENE FUSIONS OF ESR1 AND CCDC170 FOR DETERMINING INCREASED RESISTANCE TO ENDOCRINE THERAPY AND FOR CANCER TREATMENT | ESR1, CCDC22, CCDC6 | ERBB2 711/4885EGFR 722/4885SRC 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.